Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,869,288
  • Shares Outstanding, K 2,531,900
  • Annual Sales, $ 23,002 M
  • Annual Income, $ 3,499 M
  • 36-Month Beta 0.75
  • Price/Sales 3.68
  • Price/Cash Flow 10.82
  • Price/Book 5.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.61 +2.61%
on 11/10/17
34.81 -3.88%
on 10/20/17
-1.32 (-3.80%)
since 10/17/17
3-Month
28.78 +16.26%
on 08/21/17
34.94 -4.24%
on 10/16/17
+4.38 (+15.06%)
since 08/17/17
52-Week
25.55 +30.96%
on 12/07/16
35.60 -6.01%
on 06/22/17
+6.11 (+22.34%)
since 11/17/16

Most Recent Stories

More News
Cancer Space Update: Label Expansion for Three Major Drugs

This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

AVEO : 3.11 (+1.63%)
CELG : 104.10 (+0.73%)
AZN : 33.46 (-0.18%)
BLUE : 163.20 (+1.90%)
MRK : 55.20 (+0.05%)
RHHBY : 29.1000 (+0.71%)
PFE : 35.37 (-0.53%)
Acorda Reports Death in Parkinson's Trials, Stock Down 40%

Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.

AZN : 33.46 (-0.18%)
ADMS : 28.41 (+2.60%)
PRTA : 51.93 (-5.25%)
ACOR : 17.80 (+3.19%)
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
LLY : 82.89 (-0.66%)
PFE : 35.37 (-0.53%)
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

BAYRY : 31.7900 (-0.05%)
AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
LLY : 82.89 (-0.66%)
PCRX : 40.25 (+1.90%)
BMY : 61.32 (-0.89%)
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

AZN : 33.46 (-0.18%)
TEVA : 13.84 (+8.21%)
AMGN : 170.00 (-0.45%)
GSK : 35.06 (-0.37%)
FASLODEX(R) (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

--Second Approval in Three Months Expands Treatment Options for Women with HR+, HER2- Advanced Breast Cancer

AZN : 33.46 (-0.18%)
FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma

AstraZeneca (NYSE: AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved FASENRA(TM) (benralizumab) for the...

AZN : 33.46 (-0.18%)
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
AGN : 174.88 (+0.04%)
ALKS : 48.40 (+1.36%)
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

AZN : 33.46 (-0.18%)
NVO : 50.91 (+0.81%)
MRK : 55.20 (+0.05%)
LLY : 82.89 (-0.66%)
PFE : 35.37 (-0.53%)
SNY : 44.54 (-0.25%)
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

LGND : 140.31 (-0.99%)
PDLI : 2.84 (-0.35%)
AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 33.63
1st Resistance Point 33.54
Last Price 33.46
1st Support Level 33.33
2nd Support Level 33.20

See More

52-Week High 35.60
Last Price 33.46
Fibonacci 61.8% 31.76
Fibonacci 50% 30.57
Fibonacci 38.2% 29.39
52-Week Low 25.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart